2026 年至 2035 年血液癌症診斷的市場機會、成長要素、產業趨勢分析與預測。

全球血液腫瘤診斷市場預計到 2025 年將達到 138 億美元，預計到 2035 年將以 6.8% 的複合年成長率成長至 266 億美元。

全球骨髓惡性腫瘤率的不斷上升是推動市場成長的主要因素，人口結構變化和疾病檢測能力的提高也起到了促進作用。對早期準確診斷日益成長的需求促使醫療系統優先考慮能夠實現及時干預並改善患者預後的先進診斷解決方案。人們對癌症篩檢和早期檢測重要性的認知不斷提高，進一步推動了診斷檢測數量的成長。診斷平台的技術進步顯著提高了準確性、靈敏度和結果出具速度，從而能夠更深入地了解疾病並制定個人化的治療方案。分子診斷和定序技術等先進工具的整合正在改變診斷工作流程並改善臨床決策。此外，常規檢測方案的日益普及確保了所有醫療機構的持續需求。研發投入的增加以及對更有效率診斷方法的需求，持續強化血液腫瘤診斷市場的整體成長動能。

預計到2025年，檢測試劑盒和試劑領域的銷售額將達到84億美元。該領域是診斷生態系統的重要組成部分，可支持疾病相關生物標記的檢測和測量。這些產品廣泛應用於多種調查方法，是臨床和調查應用的必備品。其標準化設計、與實驗室系統的兼容性以及即用型設計有助於提高操作效率並確保檢測結果的一致性。對準確且可重複的診斷結果的持續需求，不斷推動該領域的成長。

預計到2025年，血液檢測市場規模將達53億美元。該市場在診斷過程中發揮著至關重要的作用，透過對血液參數的常規分析，可以早期評估異常情況。這是識別潛在健康問題並指導後續診斷程序的第一步。血液檢測在醫療機構的廣泛應用，有助於檢測量的成長和穩定。將其納入標準臨床實踐，確保了對篩檢、監測和評估的持續需求。

到2025年，北美血液腫瘤診斷市佔率將達到46.5%。該地區血液腫瘤診斷市場呈現強勁成長勢頭，主要受骨髓惡性腫瘤負擔日益加重的推動。白血病、淋巴瘤和多發性骨髓瘤等疾病發生率的上升顯著推高了北美地區對診斷解決方案的需求。人口老化和生活方式相關風​​險因素的變化等人口趨勢進一步促進了診斷率的提升。患者數量的增加使得快速準確檢測的需求更加迫切，促使醫療機構和專業實驗室採用先進的診斷技術。此外，該地區完善的醫療保健體系和較高的人均醫療保健支出也為廣泛普及先進的診斷技術提供了保障。

目錄

第1章：調查方法

• 研究途徑
• 品質改進計劃
  • GMI人工智慧政策及對資料完整性的承諾
    • 資訊來源一致性協議
• 調查過程和可靠性評分
  • 調查過程的組成部分
  • 評分組成部分
• 數據收集
  • 主要來源部分列表
• 資料探勘資訊來源
  • 付費資訊來源
    • 區域資訊來源
• 基本估算和計算方法
  • 每種方法中基準年的計算
• 預測模型
  • 量化市場影響分析
    • 生長參數對預測的數學影響
• 關於調查透明度的補充信息
  • 資訊來源歸屬框架
  • 品質保證指標
  • 對信任的承諾

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 血液癌症發生率上升
    • 癌症診斷技術的進步
    • 提高公眾意識和早期篩檢計劃
  • 產業潛在風險與挑戰
    • 先進診斷技術高成本
    • 嚴格的法規環境
  • 市場機遇
    • 開發即時檢測和分散式檢查解決方案
• 成長潛力分析
• 監理情勢（基於初步調查）
• 技術趨勢（基於初步調查）
  • 當前技術趨勢
    • 分子診斷（基於PCR的檢測）的整合
    • 次世代定序(NGS) 檢測板的應用日益廣泛
  • 新興技術
    • 液態生物檢體
    • 即時診斷和分散式診斷平台
• 未來市場趨勢（基於初步研究）
• 人工智慧和生成式人工智慧對市場的影響（基於初步研究）
• 2025年價格分析（基於初步調查）
• 波特五力分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 世界
  • 北美洲
  • 歐洲
  • 亞太地區
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 業務拓展計劃

第5章 市場估價與預測：依產品分類，2022-2035年

• 裝置
• 檢測試劑盒和試劑

第6章 市場估計與預測：依測試類型分類，2022-2035年

• 驗血
• 影像檢查
• 切片檢查
• 分子檢測

第7章 市場估計與預測：依癌症類型分類，2022-2035年

• 白血病
• 淋巴瘤
• 多發性骨髓瘤

第8章 市場估算與預測：依最終用途分類，2022-2035年

• 醫院
• 診斷檢查室
• 診斷影像中心
• 癌症研究機構

第9章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Abbott Laboratories
• Adaptive Biotechnologies Corporation
• Agilent Technologies, Inc.
• Beckman Coulter, Inc.
• Becton, Dickinson and Company（BD）
• Bio Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• GE Healthcare
• Guardant Health, Inc.
• Invivoscribe Technologies, Inc.
• Precipio Diagnostics
• QIAGEN NV
• Sysmex Corporation
• Thermo Fisher Scientific Inc
• Exact Sciences Corporation

The Global Blood Cancer Diagnostics Market was valued at USD 13.8 billion in 2025 and is estimated to grow at a CAGR of 6.8% to reach USD 26.6 billion by 2035.

Market growth is driven by the increasing global incidence of hematological malignancies, supported by demographic shifts and improvements in disease detection capabilities. The growing need for early and accurate diagnosis is encouraging healthcare systems to prioritize advanced diagnostic solutions that enable timely intervention and improved patient outcomes. Rising awareness regarding cancer screening and the importance of early detection is further increasing the volume of diagnostic testing. Technological advancements in diagnostic platforms are significantly enhancing precision, sensitivity, and turnaround time, enabling better disease characterization and personalized treatment planning. The integration of advanced tools such as molecular diagnostics and sequencing technologies is transforming diagnostic workflows and improving clinical decision-making. In addition, expanding adoption of routine testing protocols is ensuring consistent demand across healthcare settings. Increasing investments in research and development, combined with the need for more efficient diagnostic approaches, continue to strengthen the overall growth trajectory of the blood cancer diagnostics market.

The assay kits and reagents segment generated USD 8.4 billion in 2025. This segment represents a critical component of the diagnostic ecosystem, supporting the detection and measurement of disease-related biomarkers. These products are widely utilized across multiple diagnostic methodologies and are essential for both clinical and research applications. Their standardized design, compatibility with laboratory systems, and ready-to-use formats contribute to operational efficiency and consistent testing outcomes. The ongoing demand for accurate and reproducible diagnostic results continues to drive adoption within this segment.

The blood tests segment accounted for USD 5.3 billion in 2025. This segment plays a foundational role in the diagnostic pathway by enabling the initial assessment of abnormalities through routine analysis of blood parameters. It serves as a primary step in identifying potential health concerns and guiding further diagnostic procedures. The widespread use of blood testing across healthcare facilities contributes to high testing volumes and consistent utilization. Its integration into standard clinical practices ensures ongoing demand for screening, monitoring, and evaluation purposes.

North America Blood Cancer Diagnostics Market accounted for 46.5% share in 2025. The blood cancer diagnostics market in the region is witnessing strong growth momentum, supported by the increasing burden of hematological malignancies. The rising occurrence of conditions such as leukemia, lymphoma, and multiple myeloma is significantly contributing to the demand for diagnostic solutions across North America. Demographic trends, including an aging population and evolving lifestyle-related risk factors, are further driving higher diagnosis rates. Growing patient volumes are increasing the urgency for timely and precise detection, leading to greater adoption of advanced diagnostic technologies across healthcare facilities and specialized laboratories. Additionally, the region benefits from well-established healthcare systems and high healthcare expenditure per capita, enabling broader access to advanced diagnostic capabilities.

Key players operating in the Blood Cancer Diagnostics Market include F. Hoffmann La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company (BD), Agilent Technologies, Inc., QIAGEN N.V., Bio Rad Laboratories, Inc., Sysmex Corporation, GE Healthcare, Guardant Health, Inc., Adaptive Biotechnologies Corporation, Invivoscribe Technologies, Inc., Precipio Diagnostics, and Exact Sciences Corporation. Companies in the Blood Cancer Diagnostics Market are focusing on innovation, strategic partnerships, and portfolio expansion to strengthen their competitive position. Significant investments are being made in research and development to enhance diagnostic accuracy and introduce advanced technologies. Collaborations with healthcare providers and research institutions are helping companies expand their clinical capabilities and improve product adoption. Firms are also working on expanding their global presence through geographic diversification and distribution network enhancements. Regulatory compliance and quality assurance remain key priorities to ensure product reliability.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 3600 synopsis
• 2.2 Key market trends
  • 2.2.1 Product trends
  • 2.2.2 Test type trends
  • 2.2.3 Cancer type trends
  • 2.2.4 End use trends
  • 2.2.5 Regional trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of blood cancer
    • 3.2.1.2 Advancements in cancer diagnostic technologies
    • 3.2.1.3 Growing awareness and early screening programs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of advanced diagnostics
    • 3.2.2.2 Stringent regulatory scenario
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of point-of-care and decentralized testing solutions
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape (Driven by primary research)
  • 3.5.1 Current technological trends
    • 3.5.1.1 Integration of Molecular Diagnostics (PCR Based Tests)
    • 3.5.1.2 Growing Adoption of Next Generation Sequencing (NGS) Panels
  • 3.5.2 Emerging technologies
    • 3.5.2.1 Liquid Biopsy for Blood Cancer Monitoring
    • 3.5.2.2 Point of Care and Decentralized Diagnostic Platforms
• 3.6 Future market trends (Driven by primary research)
• 3.7 Impact of AI and Generative AI on the market (Driven by primary research)
• 3.8 Pricing analysis, 2025 (Driven by primary research)
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Assay kits and reagents

Chapter 6 Market Estimates and Forecast, By Test type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Blood tests
• 6.3 Imaging tests
• 6.4 Biopsy
• 6.5 Molecular test

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Leukemia
• 7.3 Lymphoma
• 7.4 Myeloma

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Diagnostic laboratories
• 8.4 Diagnostic imaging centers
• 8.5 Cancer research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Adaptive Biotechnologies Corporation
• 10.3 Agilent Technologies, Inc.
• 10.4 Beckman Coulter, Inc.
• 10.5 Becton, Dickinson and Company (BD)
• 10.6 Bio Rad Laboratories, Inc.
• 10.7 F. Hoffmann-La Roche Ltd.
• 10.8 GE Healthcare
• 10.9 Guardant Health, Inc.
• 10.10 Invivoscribe Technologies, Inc.
• 10.11 Precipio Diagnostics
• 10.12 QIAGEN N.V.
• 10.13 Sysmex Corporation
• 10.14 Thermo Fisher Scientific Inc
• 10.15 Exact Sciences Corporation